

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

Resolutions Passed at the 4th Board Meeting for FY2019

The board of directors (the “Board”) of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited collectively and individually accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “**Company**”) had on 5 July 2019 duly convened its 4th board meeting for financial year ending 31 December 2019 (“FY2019”). The following resolutions were discussed and passed by the 7 directors out of the full board of 7 directors.

The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Memorandum & Articles of Association of the Company, and the following resolutions were passed:

1. That, due to the cessation of Mr. Vincent Toe Teow Heng as an Independent Director and pursuant to the appointment of Mr. Wong Gang as an Independent Director of the Company approved at the Annual General Meeting for financial year ended 31 December 2018 held on 15 May 2019, the change of Board Committee members of the Company be approved as follows:

Mr. Wong Gang replaces Mr. Vincent Toe Teow Heng as Chairman of Remuneration Committee, a member of Audit Committee and a member of Nomination Committee.

2. That the appointment of Mr. Wang Xin as Deputy General Manager of the Company be approved;

Mr. Wang Xin, born in October 1970, graduated from Tianjin Traditional Chinese Medicine College (currently known as Tianjin University of Traditional Chinese Medicine), majoring in Traditional Chinese Medicine and holds a bachelor degree and is also a Senior Engineer (senior title). From July 1993 to November 2011, he successively held the positions as Minister of Technology Department, Minister of Production Department, Director of Technical Quality Centre, Chief Engineer, Executive Deputy Director, Director and Deputy Secretary of Communist Party of China (the “**CPC**”) of Tianjin Long Shun Rong Pharmaceutical Factory. From November 2011 to present, he is General Manager and Deputy Secretary of Party Branch of CPC of Medicine Co. of the Company. From September 2015 to September 2018, he held the position as the General Manager of Tianjin Darentang (Bozhou) Chinese Medicine Co., Ltd. From March 2017 to present, he holds the position of Minister of Medicine Department of the Company. From August 2017 to present, he is Assistant General Manager of the Company, and holds concurrent posts as Minister of Medicine Department and Minister of the Department of Administrative Affairs of the Company.

3. That the appointment of Mr. Ni Zhenguo as Deputy General Manager of the Company be approved;

Mr. Ni Zhenguo, born in November 1969, graduated from Tianjin University of Traditional Chinese Medicine, majoring in Traditional Chinese Medicine and holds a bachelor degree and a master degree of Business Administration. He is also a Senior Engineer. From July 1992 to November 2006, he successively held the positions as Cadre of Pharmaceutical Research Room, Regional Manager of Sales Department, Minister of Planning Department and Deputy Director of Marketing Centre of Tianjin Long Shun Rong Pharmaceutical Factory. From November 2006 to October 2011, he successively held the positions as Marketing Director, Sales Director and Assistant to the

Director of the sales company of Le Ren Tang Pharmaceutical Factory. From October 2011 to April 2013, he held the position as Deputy Minister of Marketing Department of the Company. From April 2013 to present, he holds the position as Marketing Director of the Company.

By order of the Board
5 July 2019